NCT04959305

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

A Multicenter, Randomized, Double-blind, Parallel, Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 245 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	HCP1803-3	Take it once daily for 8 weeks orally.
DRUG	RLD2003	Take it once daily for 8 weeks orally.
DRUG	RLD2004	Take it once daily for 8 weeks orally.
DRUG	RLD2005	Take it once daily for 8 weeks orally.
DRUG	HPP2003-3	Placebo drug. Take it once daily for 8 weeks orally.
DRUG	HPP2005	Placebo drug. Take it once daily for 8 weeks orally.

Timeline

• Start date: 2021-04-22
• Primary completion: 2022-02-28
• Completion: 2022-02-28
• First posted: 2021-07-13
• Last updated: 2022-07-14

Locations

1 site across 1 country: South Korea